Skip to main content
Log in

Serum Levels of TRAP5b, a New Bone Resorption Marker Unaffected by Renal Dysfunction, as a Useful Marker of Cortical Bone Loss in Hemodialysis Patients

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

Tartrate-resistant acid phosphatase (TRAP) 5b is a new marker of bone resorption that is unaffected by renal dysfunction. The significance of TRAP5b was assessed in hemodialysis (HD) patients. Serum concentrations of TRAP5b and cross-linked N-telopeptide of type I collagen (NTX) were determined as bone resorption markers, and those of bone alkaline phosphatase (BAP) and intact osteocalcin (OC) were measured as bone formation markers in 58 HD patients. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry twice in the distal third of the radius, with a 2-year interval between measurements. Serum TRAP5b correlated significantly with BAP, intact OC, intact parathyroid hormone (PTH), and especially serum NTX. TRAP5b, NTX, BAP, and intact OC all correlated significantly with BMD at the time of the second measurement; and TRAP5b, NTX, and intact OC, but not BAP and intact PTH, correlated significantly with the annual change in BMD during the 2-year period. Among the bone markers, patients in the highest tertile for serum TRAP5b and intact OC showed the fastest rate of cortical bone loss. The sensitivity and specificity for detection of rapid bone loss were 57.9% and 76.9%, respectively, for serum TRAP5b. Measurement of serum TRAP5b, as well as intact OC, may be a clinically relevant assay for estimation of bone metabolic status in HD patients, although serum intact OC accumulates in uremic serum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Piraino B, Chen T, Coorperstein L, Segre G, Puschett J (1998) Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 30:57–62

    Google Scholar 

  2. Ballanti P, Coen G, Mazzaferro S, Taggi F, Giustini M, Calabria S, Ferrannini M, Bonucci E (2001) Histomorphometric assessment of bone turnover in uremic patients: comparison between activation frequency and bone formation rate. Histopathology 38:571–583

    Article  PubMed  CAS  Google Scholar 

  3. Maeno Y, Inaba M, Okuno S, Yamakawa T, Ishimura E, Nishizawa Y (2005) Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients. Clin Chem 51:2312–2317

    Article  PubMed  Google Scholar 

  4. Okuno S, Inaba M, Kitatani K, Ishimura E, Yamakawa T, Nishizawa Y (2005) Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporos Int 16:501–509

    Article  PubMed  Google Scholar 

  5. Nagasue K, Inaba M, Okuno S, Kitatani K, Imanishi Y, Ishimura E, Miki T, Kim M, Nishizawa Y (2003) Serum N-terminal midfragment vs. intact osteocalcin immunoradiometric assay as markers for bone turnover and bone loss in hemodialysis patients. Biomed Pharmacother 57:98–104

    Article  PubMed  CAS  Google Scholar 

  6. Chiaki O, Yoshikata I, Kikuchi R, Nakayama M, Uchiyama Y, Hirahara F, Gorai I (2000) The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Miner Res 8:1537–1544

    Article  Google Scholar 

  7. Braga de Castro Machado A, Hannon R, Eastell R (1999) Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 14:602–608

    Article  PubMed  CAS  Google Scholar 

  8. Looker AC, Bauer DC, Chesnut CH III, Gundberg CM, Hochberg MC, Klee G (2000) Clinical use of biochemical markers of bone remodeling: current status and fracture directions. Osteoporos Int 11:467–480

    Article  PubMed  CAS  Google Scholar 

  9. Ueda M, Inaba M, Okuno S, Maeno Y, Ishimura E, Yamakawa T, Nishizawa Y (2005) Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sci 77:1130–1139

    Article  PubMed  Google Scholar 

  10. Chao TY, Lin YF, Janckila AJ, Yam LT (2003) Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 41:1052–1059

    Article  PubMed  Google Scholar 

  11. Halleen JM, Ylipahkala H, Alatalo SL, Jancklia AJ, Heikkinen JE, Suominen H, Cheng S, Väänänen HK (2002) Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 71:20–25

    Article  PubMed  CAS  Google Scholar 

  12. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK (2000) Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15:1337–1345

    Article  PubMed  CAS  Google Scholar 

  13. Väänänen HK, Zhao H, Mulari M, Halleen JM (2000) The cell biology of osteoclast function. J Cell Sci 113:377–381

    PubMed  Google Scholar 

  14. Halleen JM, Hentunen TA, Karp M, Kakonen SM, Pettersson K, Väänänen HK (1998) Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay. J Bone Miner Res 113:683–687

    Article  Google Scholar 

  15. Chamberlain P, Compston J, Cox TM (1995) Generation and characterization of monoclonal antibodies to human type-5 tartrate-resistant acid phosphatase: development of a specific immunoassay of the isoenzyme in serum. Clin Chem 41:1495–1499

    PubMed  CAS  Google Scholar 

  16. Miyazaki S, Igarashi M, Nagata A, Tominaga Y, Onodera K, Komoda T (2003) Development of immunoassays for type-5 tartrate-resistant acid phosphatase in human serum. Clin Chim Acta 329:109–115

    Article  PubMed  CAS  Google Scholar 

  17. Nakasato YR, Janckila AJ, Halleen JM, Vaananen HK, Walton SP, Yam LT (1999) Clinical significance of immunoassays for type-5 tartrate-resistant acid phosphatase. Clin Chem 45:2150–2157

    PubMed  CAS  Google Scholar 

  18. Miura T, Ohashi T, Omote M, Akioka H, Igarashi Y (2005) Stability of TRAP5b activity in serum [in Japanese]. Osteoporos Jpn 13:223

    Google Scholar 

  19. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, Nishizawa Y (2000) Persistent increase in bone turnover in Graves’ patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 85:4517–4561

    Article  Google Scholar 

  20. Inaba M, Terada M, Nishizawa Y, Shioi A, Ishimura E, Otani S Morii H (1999) Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism. Metabolism 48:904–909

    Article  PubMed  CAS  Google Scholar 

  21. Inaba M, Nishizawa Y, Mita K, Kumeda Y, Emoto M, Kawagishi T, Ishimura E, Nakatsuka K, Shioi A, Nishizawa Y (1999) Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporos Int 9:525–531

    Article  PubMed  CAS  Google Scholar 

  22. Ohashi T, Igarashi Y, Mochizuki Y, Miura T, Inaba N, Katayama K, Tomonaga T, Nomura F (2007) Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b. Clin Chim Acta 376:205–212

    Article  PubMed  Google Scholar 

  23. Nishizawa Y, Inaba M, Ishii M, Yamashita H, Miki T, Goto H (2008) Reference intervals of the serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects. J Bone Miner Metab (in press)

  24. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lauzure C, D’Amour P (1998) A non-(1–84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44:805–809

    PubMed  CAS  Google Scholar 

  25. Arnaud CD, Pun KK (1992) Metabolism and assay of parathyroid hormone. In: Coe FL, Favus MJ (eds) Disorders of bone and mineral metabolism. Raven Press, New York, pp 107–122

    Google Scholar 

  26. Gertz BJ, Clenens JD, Holland SD, Yuan W, Greenspan S (1998) Application of a new serum assay for type 1 collagen crosslinked N-telopeptides: assessment of clinical changes in bone turnover with or without alendronate treatment. Calcif Tissue Int 63:102–106

    Article  PubMed  CAS  Google Scholar 

  27. Clemems JD, Herrick MV, Singer FR, Eyre DR (1997) Evidence that serum NTX (collagen–type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43:2058–2063

    Google Scholar 

  28. Gomes B Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff YD, Kung VY (1995) Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41:1560–1566

    Google Scholar 

  29. Takahashi M, Kushida K, Nagano A, Inoue T (2000) Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin Chim Acta 294:67–76

    Article  PubMed  CAS  Google Scholar 

  30. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform as a marker of bone resorption. Bone 34:187–194

    Article  PubMed  CAS  Google Scholar 

  31. Yoshimura N, Nakatsuka K, Saitoh S, Nishizawa Y, Uchiyama M, Miura M (2002) Serum cross-linked N-telopeptide of type 1 collagen (NTX) and serum amino-terminal propeptide of type 1 procollagen (PINP) in residents of a rural community in Japan: reference values classified by age and sex. Osteoporos Jpn 3:171–176

    Google Scholar 

  32. Suzuki K, Kurose T, Takizawa M, Maruyama M, Ushikawa K, Kikuyama M, Sugimoto C, Seino Y, Nagamatsu S, Ishida H (2005) Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. Diabetes Res Clin Pract 68:117–125

    Article  PubMed  Google Scholar 

  33. Inaba M, Nakatsuka K, Imanishi Y, Watanabe M, Mamiya Y, Ishimura E, Nishizawa Y (2003) Technical and clinical characterization of the Bio-PTH(1–84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem 50:385–390

    Article  PubMed  Google Scholar 

  34. Inaba M, Okuno S, Imanishi Y, Ueda M, Yamakawa T, Ishimura E, Nishizawa Y (2005) Significance of bio-intact PTH(1–84) assay in hemodialysis patients. Osteoporos Int 16:517–525

    Article  PubMed  Google Scholar 

  35. Yamaguchi T, Kanno E, Tsubota J, Shiomi T, Nakai M, Hattori S (1996) Retrospective study on usefulness of radius and lumbar bone density in the separation of HD patients with fractures from those without fractures. Bone 19:549–555

    Article  PubMed  CAS  Google Scholar 

  36. Stein MS, Packham DK, Ebeling PR, Wark JD, Becker GJ (1996) Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney 28:515–522

    Article  CAS  Google Scholar 

  37. Miki T, Morita A, Nakatsuka K, Tabata T, Inoue T, Nishizawa Y, Morii H (1997) Changes in bone mineral density in patients on HD due to chronic glomerulonephritis. Osteoporos Int 7(Suppl 3):193–196

    Google Scholar 

  38. Lindergard B, Cederholm B (1994) Long-time follow-up (10–22 years) of bone mineral density in patients on uninterrupted HD for more than 10 years. Bone Miner 25(Suppl 2):38

    Google Scholar 

  39. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ (2005) Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 1:6–17

    Article  Google Scholar 

  40. Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Väänänen HK, Akesson K, Obrant KJ (2004) Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19:386–393

    Article  PubMed  CAS  Google Scholar 

  41. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, Väänänen HK (2001) Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47:597–600

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Masaaki Inaba.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shidara, K., Inaba, M., Okuno, S. et al. Serum Levels of TRAP5b, a New Bone Resorption Marker Unaffected by Renal Dysfunction, as a Useful Marker of Cortical Bone Loss in Hemodialysis Patients. Calcif Tissue Int 82, 278–287 (2008). https://doi.org/10.1007/s00223-008-9127-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-008-9127-4

Keywords

Navigation